

49
10 P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Soppet et al.

Application Serial No.: 09/236,468

Art Unit: 1646

Filed: January 25, 1999

Examiner: L. Spector

For: G-Protein Parathyroid Hormone
Receptor HLTG74

Attorney Docket No.: PF201D1

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references C2, C4, and C15 listed on the attached form PTO/SB/08A. A copy of reference C15 is enclosed.

Copies of references C2 and C4 were previously submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 08/468,011, filed on June 6, 1995, to which the instant application claims priority under 35 U.S.C. § 120, as well as in the instant application. However, Applicants inadvertently directed the attention of the Examiner to slightly incorrect page number ranges in references C2 and C4. Applicants wish to bring these obvious typographical errors to the attention of the Examiner. The correct page number ranges are now recited on the PTO/SB/08A attached hereto. Accordingly, no copies of references C2 and C4 are enclosed.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

September 1, 2000
Date

Joseph J. Kenny
Joseph J. Kenny (Reg. No. 43,710)
Agent for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5800

Enclosures

MMW/JJK/DS/lcc